Menu
Enrolling by invitation NCT07335432

RCT - Efficacy of Intravenous Vitamin C Versus Placebo on Estimated Blood Loss in Total Abdominal Hysterectomy

No phase Interventional Myoma;Uterus Adenomyosis of Uterus

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vitamin C (Ascorbic Acid).
Who it may be relevant to
Registry conditions: Myoma;Uterus, Adenomyosis of Uterus. Basic parameters: from 20 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Thailand
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of Intravenous Vitamin C Versus Placebo on Estimated Blood Loss in Total Abdominal Hysterectomy

Overview

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times. The primary outcome was to compare intraoperative blood loss between patients who received intravenous Vitamin C and those who did not, following an abdominal hysterectomy under general anesthesia. Intraoperative estimated blood loss (EBL) was meticulously quantified by weighing surgical gauze and measuring suction canister volumes. The secondary outcomes were to evaluate the potential benefits of Vitamin C administration, including: * Reduction in the decline of hematocrit levels after surgery. * Reduction of the length of hospital stay

Interventions

  • Dietary supplement Vitamin C (Ascorbic Acid)
    Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision.

Primary outcome measures

  • Intraoperative estimate blood loss [Time frame: intraoperative]

Eligibility criteria

Inclusion criteria

  • Female patients who underwent total abdominal hysterectomy
  • No bleeding tendency.
  • No history of anticoagulant or thrombolytic drug use
  • No contraindications to vitamin C supplementation

Exclusion criteria

  • Inability to communicate in the Thai language.
  • Underwent total abdominal hysterectomy due to gynecologic malignancy.
  • Required emergency total abdominal hysterectomy.
  • History of vitamin C supplementation within 2 weeks prior to surgery.
  • History of smoking.
  • Previous abdominal surgery, such as bowel surgery, cesarean section

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Thailand · 1 center
  • Queen Savang Vadhana Memorial hospital — Si Racha

Identifiers

NCT: NCT07335432 · 012/2567

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗